Which weight-loss medication class should be avoided in patients with cardiovascular disease?

• A. Orlistat
• B. Sympathomimetics
• C. Topiramate
• D. Naltrexone/Bupropion

Answer: (B)

The main idea here is how different weight-loss meds affect the heart. Sympathomimetics stimulate the sympathetic nervous system, which raises heart rate and blood pressure and increases the heart’s workload. In people with cardiovascular disease, this added strain can trigger chest pain, arrhythmias, or other serious events, so these drugs are avoided in this group.

Other options work in ways that don’t acutely boost sympathetic activity. Orlistat acts in the gut to block fat absorption and has minimal cardiovascular impact. Topiramate reduces appetite through central mechanisms without causing dangerous increases in heart rate or blood pressure. Naltrexone/bupropion affects appetite via brain pathways and has its own risk profile, but it isn’t a direct stimulant like sympathomimetics, so it isn’t categorically avoided for all cardiovascular disease cases.